Critical Testing Where Coinfection is High

Where coinfection is prevalent, our infectious disease assays offer the opportunity for co-testing. With the Panther system, laboratories can leverage running multiple assays from one patient sample. This flexibility helps laboratories increase efficiency and control productivity, which contributes to better healthcare management.

HIV-1 and HPV Coinfection



1 out of 2

women with HIV are **coinfected** with high-risk HPV.[2]

Women with HIV are:

5x more likely to develop **cervical cancer**.[3]

HIV-1 and HCV Coinfection



Estimated

5 **million** coinfected[4]

HIV-1 / HCV coinfected individuals are[2]:

2x as likely to develop **cirrhosis**.

6x as likely to develop end-stage **liver disease**.

Hologic
global access initiative

Together we can improve care where it is needed most.

To learn more about the Hologic Global Access Initiative and eligible countries for inclusion, contact humancare@hologic.com.

Hologic.com/GlobalAccessInitiative

References: 1. Hologic, Inc. Data on File. 2018. **2.** Vuyst HD, et al. Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. Br J Cancer. 2012;107(9):1624- 1630. **3.** Pink Ribbon Red Ribbon. Annual Report: 2014-2015. http://pinkribbonredribbon.org/ wp-content/uploads/2016/08/LU_PRRR_PrintReport_FULL_Final_low.pdf. Published 2016. Accessed June 6, 2018. **4.** The Global Fund. Global Fund and Hepatitis C Treatment. The Global Fund Thirty-Second Board Meeting; November 20-21, 2014; Montreux, Switzerland.

Revolutionary approach to diagnostic testing for resource-limited settings.

The Hologic Global Access Initiative promotes cost-effective procurement and financial sustainability while improving access to critical testing.

The Global Access Initiative is a partnership with the Clinton Health Access Initiative, Inc. (CHAI) and MedAccess (backed by the UK government) to mitigate the burden of viral diseases in areas with high prevalence by improving health markets with greater access to testing using the Panther® system.

All eligible countries and organizations are able to procure **all-inclusive testing** with no upfront cost or capital expenditure.

$12.00 per patient sample includes*:

- Instrument placement
- Reagents and consumables
- Service and maintenance
- Freight and logistics
- Replacement tests†

* Testing Services do not include ancillary costs, for example those associated with sample collection, sample transport, laboratory staff time, laboratory infrastructure, generic lab supplies (e.g., primary collection tubes, disposable gloves, bleach, bleach bottles, bleach enhancer, waste bottles, etc.), inventory management, or general administration and overhead costs.

† One set of controls and calibrators per kit and documented instrument errors.

Aptima® Assays on the Panther System

As part of our commitment to the 90-90-90 UNAIDS goal, the Global Access Initiative includes HIV-1 testing and other viral targets. Qualified assays include:

Aptima® HIV-1 Quant Dx Assay — Aids in the diagnosis, confirmation and clinical management of HIV-1 infection. *Now WHO prequalified.*

Aptima® HCV Quant Dx Assay — Aids in the diagnosis, confirmation and clinical management of HCV infection.

Aptima® HBV Quant Assay — Aids in the clinical management of HBV infection.

Aptima® HPV Assay — Detects 14 high-risk HPV types.

Panther System Benefits

The Panther system excels in both large, centralized labs and smaller, decentralized labs. With high throughput, batch-free processing and a growing menu, the Panther system adapts in an evolving testing landscape on a single, integrated solution. The system helps maximize lab efficiencies with true sample-to-result automation, featuring random and continuous sample loading to release you from the confines of batch testing.

- Allows loading up to 120 samples at any time with no batching restrictions
- Runs up to 4 assays in parallel to manage coinfections
- Requires minimal hands-on time
- Load primary blood tubes directly on instrument
- Processes up to 320 samples in an 8-hour day
- Small footprint, highest throughput per square foot[1]
- Features an intuitive touchscreen operating system for simplified training and minimized risk of error

Infrastructure Requirements

To participate in the Hologic Global Access Initiative, laboratories must meet certain infrastructure requirements.

Physical Space
Sufficient space to accommodate the Panther system: 122 cm (w) x 81.5 cm (d) x 175 cm (h). Sufficient space to accommodate a rocker, centrifuge and cold storage for additional samples and reagents.

Electrical Requirements
An electrical connection that supports up to a 1400 W draw, with a dedicated 20-amp circuit.‡ A backup generator capable of supporting all equipment.

Air Conditioning
Central or wall-mounted air conditioning with adequate capacity to maintain a temperature between 15°C to 30°C and relative humidity from 20%-85%.

Sink
A sink or washbasin for liquid-waste disposal.

Refrigerator
One or more refrigerator(s) with temperature control, maintained at 2°C to 8°C, to store samples and reagents.

Freezer
One or more freezer(s) with temperature control, maintained at -15°C to -5°C, to store calibrators and controls.

Testing Volume Requirements

To be eligible for the Hologic Global Access Initiative, the purchasing country or organization must share a site-specific forecast for any new Panther system placement, which anticipates:

- Processing volumes that contribute to a national average of 30,000 patient samples per eligible instrument per year within 12 months of placement.§

‡ Hologic will provide an uninterrupted power supply and surge protector and make necessary electrical modifications during installation.

§ Inclusive of all eligible assays and sample types.